Table 2.
Comorbidities in our RRMS cohort.
| Patients with comorbidities at enrolment, n (%) | Total cohort (n = 173/392) | No-poly RRMS (n = 24/219) | Minor-poly RRMS (n = 61/61) | Major-poly RRMS (n = 112/112) | p-value* |
|---|---|---|---|---|---|
| Hypertension | 111 (64.3) | – | 21 (34.4) | 90 (80.4) | <0.05 |
| Dyslipidaemia | 107 (61.8) | – | 20 (32.7) | 87 (77.7) | <0.05 |
| Diabetes | 97 (56.1) | – | 17 (27.9) | 80 (71.4) | <0.05 |
| Gastrointestinal comorbidities | 94 (54.3) | 7 (29.2) | 32 (52.4) | 62 (49.1) | ns |
| Osteoporosis | 82 (47.4) | – | 30 (49.2) | 52 (46.4) | ns |
| Depression/Anxiety | 44 (25.4) | – | 17 (27.8) | 27 (24.1) | ns |
| Hypothyroidism | 40 (23.1) | – | 15 (24.5) | 25 (22.3) | ns |
| Epilepsy | 35 (20.2) | – | 11 (18) | 24 (21.4) | ns |
| Headache | 30 (17.3) | 8 (33.3) | 8 (13.1) | 14 (12.5) | ns |
| Fatigue | 28 (16.2) | 5 (20.8) | 8 (13.1) | 15 (13.4) | ns |
| Asthma/allergy | 25 (14.5) | 4 (16.7) | 7 (11.5) | 14 (12.5) | ns |
| Urinary dysfunction | 23 (13.3) | – | 8 (13.1) | 15 (13.4) | ns |
*
via chi-square test, it is calculated between Minor-poly RRMS and Major-poly RRMS group.
RRMS, relapsing–remitting multiple sclerosis